期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

An open-label pilot study with high-dose thiamine in Parkinson's disease 被引量：1

An open-label pilot study with high-dose thiamine in Parkinson's disease
下载PDF
导出
摘要 Parkinson’s disease（PD）is a progressive neurodegenerative disorder clinically characterized by motor symptoms（bradykinesia,tremor,rigidity,postural instability）and non-motor symptoms（hyposmia,sleep disorders,autonomic and sphincteric dysfunctions,fatigue,pain,depression,and cognitive disorders）（Sprenger and Poewe,2013）. Parkinson’s disease（PD）is a progressive neurodegenerative disorder clinically characterized by motor symptoms（bradykinesia,tremor,rigidity,postural instability）and non-motor symptoms（hyposmia,sleep disorders,autonomic and sphincteric dysfunctions,fatigue,pain,depression,and cognitive disorders）（Sprenger and Poewe,2013）.
作者 Antonio Costantini Roberto Fancellu
机构地区 Department of Neurological Rehabilitation Unit of Neurology
出处 《Neural Regeneration Research》 SCIE CAS CSCD 2016年第3期406-407,共2页 中国神经再生研究（英文版）
关键词 label tremor autonomic instability pilot fatigue rigidity progressive paired dopamine label tremor autonomic instability pilot fatigue rigidity progressive paired dopamine
分类号 R742.5 [医药卫生—神经病学与精神病学]
  • 相关文献

参考文献14

  • 1Brandis KA, Holmes IF, England SJ, Sharma N, Kukreja L, DebBurman SK (2006) alpha-Synuclein fission yeast model: concentration-dependent aggregation without plasma membrane localization or toxicity. J Mol Neurosci 28:179-191.
  • 2Butterworth RF (2003) Thiamin deficiency and brain disorders. Nutr Res Rev 16:277-284.
  • 3Cilia R, Akpalu A, Sarfo FS, Cham M, Amboni M, Cereda E, Fabbri M, Adjei P, Akassi J, Bonetti A, Pezzoli G (2014) The modern pre-levodopa era of Parkin- son's disease: insights into motor complications from sub-Saharan Africa. Brain 137:2731-2742.
  • 4Costantini A, Pala MI, Grossi E, Mondonico S, Ercoli Cardelli L, Jenner C, Proietti S, Colangeli M, Fancellu R (2015) Long-term treatment with high-dose thia- mine in Parkinson disease: an open-label pilot study. J Altern Complement Med 21:740-747.
  • 5Jhala SS, Hazell AS (2011). Modeling neurodegenerative disease pathophysiology in thiamine deficiency: consequences of impaired oxidative metabolism. Neu- rochem Int 58:248-260.
  • 6Jim6nez-Jim6nez FJ, Molina JA, Herntnz A, Fernindez-Vivancos E, de Bustos F, Barcenilla B, G6mez-Escalonilla C, Zurdo M, Berbel A, Villanueva C (1999) Cerebrospinal fluid levels of thiamine in patients with Parkinson's disease. Neu- rosci Lett 271:33-36.
  • 7Kono S, Miyajima H, Yoshida K, Togawa A, Shirakawa K, Suzuki H (2009) Muta- tions in a thiamine-transporter gene and Wernicke's-like encephalopathy. N Engl J Med 360:1792-1794.
  • 8Kordower JH, Olanow CW, Dodiya HB, Chu Y, Beach TG, Adler CH, Haniday GM, Bartus RT (2013) Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain 136:2419-2431.
  • 9Lu'o'ng Kv, Nguy4n LT (2012) Thiamine and Parkinson's disease. J Neurol Sci 316:1-8.
  • 10Mkrtchyan G, Aleshin V, Parkhomenko Y, Kaehne T, Luigi Di Salvo M, Parroni A, Contestabile R, Vovk A, Bettendorff L, Bunik V (2015) Molecular mechanisms of the non-coenzyrne action of thiamin in brain: biochemical, structural and pathway analysis. Sci Pep 27:12583.

同被引文献4

引证文献1

二级引证文献3

Neural Regeneration Research
2016年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部